Find Out if Leqembi Is the Hero Aduhelm Wasn’t
April 2023
You’ll hear buzz about a new Alzheimer’s med, Leqembi (lecanemab).
It joins Aduhelm (aducanumab) as the second IV monoclonal antibody to treat mild Alzheimer’s disease. It’s NOT for dementia without amyloid beta plaque or more severe disease.
Aduhelm and Leqembi are being touted as “disease-modifying” because they decrease amyloid plaque. But this surrogate marker isn’t shown to improve Alzheimer’s disease yet.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote